2018 Fiscal Year Final Research Report
The role of LPCAT2 in ashma
Project/Area Number |
17K16043
|
Research Category |
Grant-in-Aid for Young Scientists (B)
|
Allocation Type | Multi-year Fund |
Research Field |
Respiratory organ internal medicine
|
Research Institution | The University of Tokyo |
Principal Investigator |
TARUI MEGUMI 東京大学, 保健・健康推進本部, 助教 (40727749)
|
Project Period (FY) |
2017-04-01 – 2019-03-31
|
Keywords | 気管支喘息 |
Outline of Final Research Achievements |
Platelet-activating factor (PAF) is a potent pro-inflammatory phospholipid mediator, which induces a smooth muscle cell contraction. Lysophosphatidylcholine acyltransferase (LPCAT)2 biosynthesizes PAF, and this is activated by PAF itself. We hypothesized that the inhibition of the PAF biosynthetic activity by LPCAT2 provided a novel target for the regulation of inflammatory disorders including bronchial asthma. We showed the inhibition of LPCAT2 using micro-RNA suppressed the activation of smooth muscle cells. However, using ovalbumin (OVA)-induced allergic asthma model in LPCAT2 deficient transgenic mice, it was not statistically significant that the lack of LPCAT2 suppressed asthma induction.
|
Free Research Field |
呼吸器
|
Academic Significance and Societal Importance of the Research Achievements |
気管支喘息は死に至ることのある疾患である。気管支喘息の治療薬は、近年の分子標的薬の発展が目覚ましいが、一方で、病態については未だ解明されていなことも多い。そのためコントロール不良な重症喘息で治療に難渋する人も多い。新しい分子を検討することは、気管支喘息の機序に迫り、補助的治療薬としての可能性につながると考えられる。
|